Brief: Bluejay Diagnostics Inc Updated Clinical And Regulatory Strategy For Symphony Il-6 Biomarker Test
19/05/2023 12:01
May 19 (Reuters) - Bluejay Diagnostics Inc BJDX.O :
* BLUEJAY DIAGNOSTICS INC - UPDATED CLINICAL AND REGULATORY
STRATEGY FOR SYMPHONY IL-6 BIOMARKER TEST TO MEASURE ACUITY IN
SEPSIS PATIENTS
* BLUEJAY DIAGNOSTICS- PLANS TO MODIFY CLINICAL TRIALS
DESIGN TO
EVALUATE SYMPHONY IL-6 AS A TOOL TO RISK STRATIFY HOSPITALIZED
SEPSIS PATIENTS
Source text for Eikon: ID:nGNX6pFKn8
Further company coverage: BJDX.O
Recent news on Bluejay Diagnostics
See all newsBrief: Bluejay Diagnostics Announces Successful Completion Of Enrollment In The Symon-II Multicenter Clinical Validation Study
Brief: Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Q1 net loss unchanged
Brief: Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial
Brief: Bluejay Diagnostics Provides Corporate Update And 2026 Strategic Outlook